Holen Sie sich die Stockscreener-App
307.51
6.74%
19.41
Handel nachbörslich:
306.00
-1.51
-0.49%
Schlusskurs vom Vortag:
$288.10
Offen:
$298.49
24-Stunden-Volumen:
461.49K
Relative Volume:
1.25
Marktkapitalisierung:
$33.70B
Einnahmen:
$3.81B
Nettoeinkommen (Verlust:
$-644.79M
KGV:
-49.28
EPS:
-6.24
Netto-Cashflow:
$-669.77M
1W Leistung:
+3.01%
1M Leistung:
+22.86%
6M Leistung:
+36.37%
1J Leistung:
+0.00%
1-Tages-Spanne:
$295.68
$307.51
1-Wochen-Bereich:
$280.11
$307.51
52-Wochen-Spanne:
$172.67
$313.29
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Firmenname
Beone Medicines Ltd Adr
Sektor
Branche
Telefon
41-616851900
Adresse
C/O BEONE MEDICINES I GMBH, BASEL
Vergleichen Sie ONC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten
BeOne Medicines (NASDAQ:ONC) Shares Gap DownWhat's Next? - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg Sells 1,190 Shares - MarketBeat
BeOne Medicines (NASDAQ:ONC) Hits New 52-Week HighHere's Why - MarketBeat
BeOne Medicines DRC earnings missed by $0.04, revenue topped estimates - Investing.com India
Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $327.56 - Defense World
Chan Henry Lee Sells 920 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Lai Wang Sells 259 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines stock hits 52-week high at 304.0 USD - Investing.com India
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Ariva
BeOne Medicines stock rises after positive EU opinion for lung cancer drug - Investing.com India
Lai Wang Sells 700 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap UpStill a Buy? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire Inc.
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages - Defense World
AFC Gamma (NASDAQ:AFCG) Shares Down 4.9% – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Stock Price Down 3.6% Following Insider Selling - MarketBeat
BeOne Medicines (NASDAQ:ONC) Receives “Outperform” Rating from Royal Bank Of Canada - Defense World
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) COO Sells 1,363 Shares of Stock - MarketBeat
BeOne Medicines stock rating reiterated at Outperform by RBC Capital - Investing.com
BeOne Medicines (NASDAQ:ONC) Stock Price Down 5.4%Here's What Happened - MarketBeat
Entergy Corp’s Shares Reel: 0.54% Quarterly Revenue Decline Amid 35.88B Market Cap - investchronicle.com
BeOne Medicines Ltd ADR (ONC) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
LLY Stock Quote Price and Forecast - CNN
H.C. Wainwright maintains neutral rating on Zymeworks stock - Investing.com India
China approves novel HER2-targeted therapy for BTC By Investing.com - Investing.com South Africa
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge By Stocktwits - Investing.com India
Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):